新华社北京11月5日电题：市场监管总局公布"守护消费"铁拳行动第二批典型案例 新华社记者赵文君 出租车电子计价器作弊、生产销售假冒"亚朵星球"枕头、非法改装电动自行车进行销售……市场监 管总局5日公布2025"守护消费"铁拳行动第二批典型案例。 出租车电子计价器属于国家实行强制检定的计量器具，其计量准确与否直接关系乘客切身利益。 在天津市市场监管委查处出租车计价器作弊系列案中，26辆出租车的电子计价器装有作弊装置，且 其中16台电子计价器超期未检定；26辆出租车的司机利用作弊装置增加计价里程，多收乘车费。天津市 市场监管委依据计量法有关规定，没收相关出租车司机涉案电子计价器及附带作弊装置共计26套、罚款 合计3.1万元，并将非法安装作弊装置的相关当事人移交公安机关。 生产销售侵犯注册商标专用权的商品，不仅侵犯商标权利人利益，也损害公平竞争的市场秩序。 在江苏省南通市通州区市场监管局查处生产销售侵犯他人注册商标专用权的枕头案中，现场查获印 有"亚朵星球"等注册商标的枕头543件、各类包装盒2206件、印有商标的产品吊牌17245件，经商标权利 人鉴定，均为侵权产品。当事人在未取得商标权利人授权的情况下，擅自生产 ...

/生物制造产业社群/ 让上下游聚在一起, 未来食农、绿色化工、大健康、美妆个护 等产业同行❤️↓ 【SynBioCon】 获 悉 ， 10月30日，华润双鹤与 华润医药 双双发布公告， 拟成立规模 5亿元 的基金。 基金将主要从事合成生物学、创新药物及生物技术领域的高增长企业投资集团拟承诺出资总额将为人民币1.23亿元，约占基金承诺出资总额的 24.6%。 同日，华润双鹤发布公 告设 立"华润双鹤产业基金"，承诺出资金额不超过8300万元， 约占 总额的 16.60 %。 不仅与呼和浩特政府成立产业基金，同样也在10月28日，华润医药牵头，并联合11家投资人及成都地方政府资金，共同设立 10亿规模 的华 润医药（成都）创新投资基金。 华润双鹤方表示，本次设立华润双鹤产业基金，旨在优化公司在合成生物等重点领域的战略布局，通过发挥与 呼和浩特市 产业发展的协同优 势， 丰富合成生物领域投资手段，达到促进创新孵化、加速产品和技术合作、获取产品商业化权益等目的 。 此次的11家LP中，不仅 包括华润系及其关联企业（华润医药科技、华润医药投资、博雅生物、华润双鹤、东阿阿胶 、润药企管 、江中药业 等）、成都市地方政府基 ...

除运送航天员外，神舟飞船还肩负着运送高价值、高时效性载荷等职责，能够更好地为我们的太空家园"添砖加瓦"。 至此，我国2025年载人航天发射任务圆满收官。这次任务是工程进入空间站应用与发展阶段的第6次载人飞行任务，也是工程立项实施以来的第37次发射任 务。截至目前，我国已有28名航天员、44人次进入太空执行飞行任务。 10月31日23时44分，我国成功发射神舟二十一号载人飞船，2025年载人航天发射任务也圆满收官。这次任务是长征系列运载火箭的第604次飞行、神舟飞船 的第21次飞行，也是华润江中旗下参灵草第12次伴随神舟飞船开启太空征程。 神舟二十一号成功发射 10月31日23时44分，搭载神舟二十一号载人飞船的长征二号F遥二十一运载火箭在酒泉卫星发射中心点火发射，约10分钟后，飞船与火箭成功分离，进入预 定轨道，航天员乘组状态良好，发射取得圆满成功。这次任务是长征系列运载火箭的第604次飞行、神舟飞船的第21次飞行。 神舟二十一号载人飞船入轨后，于11月1日3时22分，成功对接于空间站天和核心舱前向端口，整个对接过程历时约3.5小时，创造了神舟飞船与空间站交会 对接的最快纪录。 成功发射的同时，神舟飞船搭载的 ...

Core Insights - The traditional Chinese medicine sector experienced a rise of 1.47% on October 31, with Zhongsheng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - Zhongsheng Pharmaceutical (002317) closed at 19.32, up 10.02% with a trading volume of 772,500 shares and a transaction value of 1.454 billion [1] - Weikang Pharmaceutical (300878) closed at 24.91, up 8.59% with a trading volume of 79,700 shares and a transaction value of 195 million [1] - Darentang (600329) closed at 45.13, up 7.02% with a trading volume of 231,800 shares and a transaction value of 1.059 billion [1] - ST Xiangxue (300147) closed at 10.13, up 6.41% with a trading volume of 219,400 shares and a transaction value of 220 million [1] - Zhendong Pharmaceutical (300158) closed at 6.98, up 5.44% with a trading volume of 611,600 shares and a transaction value of 421 million [1] Capital Flow - The traditional Chinese medicine sector saw a net inflow of 524 million from main funds, while retail funds experienced a net outflow of 69.05 million [2] - Main funds showed significant net inflow into Zhongsheng Pharmaceutical at 318 million, while retail funds had a net outflow of 161 million [3] - Darentang had a main fund net inflow of 84.64 million, with retail funds showing a net outflow of 88.84 million [3]

Core Viewpoint - Fosun Pharma is planning to spin off its subsidiary, Fosun Antigen, for a listing on the Hong Kong Stock Exchange amid fluctuating performance and increasing debt levels [2][4]. Financial Performance - For the first three quarters of 2025, Fosun Pharma reported a revenue of 29.393 billion yuan, a decrease of 4.91% year-on-year, while net profit increased by 25.50% to 2.523 billion yuan [12]. - In 2023, Fosun Pharma's revenue was 41.4 billion yuan, down 5.81% year-on-year, and net profit fell by 36.04% to 2.386 billion yuan [11]. - The company has experienced a decline in revenue over the past few years, with 2022 revenue at 43.952 billion yuan, a 12.66% increase, but net profit decreased by 21.10% [9]. Debt and Cash Flow - As of the end of Q3 2025, Fosun Pharma had cash and cash equivalents of 11.478 billion yuan and short-term borrowings of 16.447 billion yuan, indicating tight cash flow [12]. - Fosun Antigen's debt ratio increased from 33.87% at the end of 2024 to 43.72% by mid-2025, reflecting a rise of approximately 10 percentage points in just six months [7]. Spin-off Details - The spin-off of Fosun Antigen aims to enhance its governance and sustainable development, thereby maximizing shareholder value [4]. - Fosun Antigen focuses on the research, production, and sales of human vaccines and has developed several vaccines that have been approved for sale in China [6]. Investment Initiatives - Fosun Pharma's subsidiary plans to establish a target fund with a total fundraising goal of 1 billion yuan, with Fosun Pharma contributing 100 million yuan [13]. - The fund aims to leverage partnerships with various investors to expand in innovative drugs, biopharmaceuticals, and high-end medical devices [13].

长江商报消息 ●长江商报记者 黄聪 复星医药（600196.SH、02196.HK）业绩波动下，或将迎来第四家分拆上市公司。 10月28日晚间，复星医药公告显示，公司拟筹划分拆控股子公司复星安特金于香港联交所上市。 不过，10月28日晚间，复星医药公告显示，公司控股子公司复星医药产业拟作为LP与其他11方投资人共同出资设立目标基金。目标基金计划募集资金人民币10亿元，其中：复星医药产业拟现金 公告显示，复星医药上述私募股权投资基金合伙人包括华润医药科技等华润方投资人，其他投资人包括成都重产二期基金、成都交子产业基金等。 复星安特金负债率增至43.72% 10月28日晚间，复星医药公告显示，为更好地促进本集团旗下具备一定细分行业平台能力的控股子公司企业管治水平持续提升和稳健可持续发展，从而实现股东价值最大化，本公司拟筹划分拆 复星医药表示，建议分拆上市有利于复星安特金进一步扩宽融资渠道、提升市场竞争力；同时，有利于本集团进一步深化在疫苗领域的布局，增强本集团的综合竞争力。 资料显示，复星安特金成立于2012年7月，注册地为四川省成都市，注册资本为8312.82483万元，法定代表人为王可心。 截至本公告日期，复 ...

长江商报消息●长江商报记者 黄聪 复星医药（600196.SH、02196.HK）业绩波动下，或将迎来第四家分拆上市公司。 10月28日晚间，复星医药公告显示，公司拟筹划分拆控股子公司复星安特金于香港联交所上市。 数据显示，近一年半来，复星安特金净利润累计亏损1.82亿元。同时，公司资产负债率从2024年底的 33.87%，升高至2025年上半年底的43.72%，半年时间提高了约10个百分点。 2025年前三季度，复星医药延续了增利不增收的局面，实现营业收入293.93亿元，同比下降4.91%；净 利润25.23亿元，同比增长25.50%。 而且，截至2025年三季度底，复星医药货币资金达114.78亿元，交易性金融资产达20.28亿元；短期借款 达164.47亿元，长期借款达94.31亿元。公司现金流较为紧张。 不过，10月28日晚间，复星医药公告显示，公司控股子公司复星医药产业拟作为LP与其他11方投资人 共同出资设立目标基金。目标基金计划募集资金人民币10亿元，其中：复星医药产业拟现金出资人民币 1亿元认缴目标基金中的等值财产份额。 公告显示，复星医药上述私募股权投资基金合伙人包括华润医药科技等华润方投 ...

Core Insights - The article emphasizes that the transition to the AI era is not optional but a necessary evolution for businesses to survive and thrive in a competitive landscape [5][6] - Companies that adopt AI early can achieve significant cost reductions and operational efficiencies, while those that lag behind face increasing challenges [3][4] Group 1: AI Adoption and Business Impact - AI is now viewed as a survival necessity rather than an optional technology, with leading companies achieving over 40% cost efficiency compared to slower adopters [4][6] - A significant portion of CFOs (nearly two-thirds) prioritize automation, including AI, as a strategic focus for the next 12 months, with many businesses reporting over 20% cost savings from AI implementation [3][6] - The period from 2025 to 2027 is identified as a critical window for businesses to implement AI solutions effectively, with a widening gap between high-performing and lagging companies [6][40] Group 2: Challenges Faced by Companies - Many companies struggle with unclear strategic goals, lack of actionable methods, and insufficient team capabilities, which hinder their ability to leverage AI effectively [7][27] - The article identifies three main issues: lack of clear objectives, absence of practical implementation methods, and inadequate team skills [7][27] Group 3: Practical AI Implementation - The "混沌AI院·2.0" program offers a structured 90-day support system to help companies transition from theoretical AI concepts to practical applications, focusing on measurable outcomes [8][9] - Successful participants in the program have utilized a unique "three-phase support" model to achieve tangible results in AI pilot projects [10][17] - The program emphasizes the importance of targeting a core scenario to maximize the return on AI investments, with high-frequency scenarios identified as AI-driven marketing growth, product innovation, and operational efficiency [11][13] Group 4: Community and Support - The program fosters a collaborative environment where companies can share resources and insights, enhancing their learning and implementation of AI strategies [30][36] - Over 3000 participants have benefited from the program, with a significant percentage achieving substantial results in their AI initiatives [37][40]

Core Viewpoint - The China Securities Regulatory Commission has proposed measures to enhance investor returns by encouraging listed companies to adopt share buybacks and increase dividend distributions, marking a shift towards a return-focused capital market [2][3]. Group 1: Dividend Policies and Trends - The new guidelines advocate for listed companies to implement multiple dividend distributions annually, enhancing the stability and predictability of dividends [3]. - The current policy environment is favorable for dividend investments, with a significant number of companies showing high dividend yields, particularly in a context of declining risk-free interest rates [3][4]. Group 2: High Dividend Yield Stocks - As of October 28, there are 118 stocks with a dividend yield exceeding 5%, with 6 stocks surpassing 10%, including Dongfang Yuhong at 14.1% and Guanghui Energy at 11.87% [4]. - Dongfang Yuhong has distributed a total of 5.881 billion yuan in cash dividends over the past year, while Guanghui Energy has a cumulative dividend of over 16.3 billion yuan from 2021 to 2024 [4]. Group 3: Performance of High Dividend Stocks - Among high dividend yield stocks, 24 companies reported significant net profit growth in the first three quarters, with Xiantan Co. leading at a 72.48% increase [5]. - Other notable performers include Wo Le Home with a 70.92% increase and Tapai Group with a 54.23% increase in net profit [5]. Group 4: Valuation and Growth Potential - A total of 21 stocks with high dividend yields are identified as undervalued, showing potential for significant price appreciation, with some having a price-to-earnings ratio below 20 and a price-to-book ratio below 2 [6]. - Hongcheng Environment is highlighted for its substantial growth potential, with a projected price increase of 42.83% and a stable dividend yield [6][7].

证券代码：600750 证券简称：江中药业 公告编号：2025-057 2025 年 10 月 28 日，公司与本基金及参与本基金的其他合伙人共同签署了 《合伙协议》，本次签订的《合伙协议》与前次披露的合伙协议主要条款未发生 重大变化。 三、对公司的影响及拟采取的应对措施 江中药业股份有限公司 关于参与设立华润医药产业投资基金二期 暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | 华润（成都）医药产业股权投资基金合伙企业（有限合伙） | | --- | --- | | | （暂定名，以工商核准名为准，原暂定名称为华润医药(成 | | | 都）创新投资基金合伙企业（有限合伙），以下简称"本基 | | | 金"或"该基金") | | 投资金额（万元） | 4,000 | | 投资进展情况 | 完成 终止 交易要素变更 进展 | | | 1、该基金待办理工商注册登记并于中国证券投资基金业协 会（以下简称"中基协）备案后，方可开展对外投资活动， | | | 实施过程存在 ...